EUVIMEDEUVIMED entdecken
LeserbriefOpen Access · CC BY 4.0

Selective degradation of the p53‐R175H oncogenic hotspot mutant by an RNA aptamer‐based PROTAC

Lingping Kong, Fanlu Meng, Sijin Wu, Ping Zhou, Ruixin Ge, Min Liu, Linlin Zhang, Jun Zhou, Diansheng Zhong, Songbo Xie iD

Clinical and Translational Medicine · 2023-02 · 13 (2)

DOI: 10.1002/ctm2.1191 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Clinical and Translational Medicine, online erschienen am 29.01.2023. Verfasst von Lingping Kong und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Tianjin Medical University General Hospital, Tianjin, China. Hauptthemen laut MEDLINE: Tumor Suppressor Protein p53, Aptamers, Nucleotide. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor Suppressor Protein p53Aptamers, NucleotideMutationCell Line, Tumor

Substanzen

Tumor Suppressor Protein p53Aptamers, Nucleotide

Autor:innen und Institutionen

  • Department of Medical Oncology, Tianjin Medical University General Hospital, Tianjin, China.
  • Laboratory of Molecular Modeling and Design, State Key Laboratory of Molecular Reaction Dynamics, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China.
  • Center for Cell Structure and Function, Shandong Provincial Key Laboratory of Animal Resistance Biology, Collaborative Innovation Center of Cell Biology in Universities of Shandong, College of Life Sciences, Shandong No…
  • Haihe Laboratory of Cell Ecosystem, Tianjin, China.
  • State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences, Nankai University, Tianjin, China.
  • School of Life Sciences and Medicine, Shandong University of Technology, Zibo, Shandong, China.

ORCID-Profile: Songbo Xie

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Kong, L., Meng, F., Wu, S., Zhou, P., Ge, R., Liu, M., Zhang, L., Zhou, J., Zhong, D., & Xie, S. (2023). Selective degradation of the p53‐R175H oncogenic hotspot mutant by an RNA aptamer‐based PROTAC. Clinical and Translational Medicine, 13(2). https://doi.org/10.1002/ctm2.1191

Vancouver

Kong L, Meng F, Wu S, Zhou P, Ge R, Liu M, et al. Selective degradation of the p53‐R175H oncogenic hotspot mutant by an RNA aptamer‐based PROTAC. Clinical and Translational Medicine. 2023;13(2). doi:10.1002/ctm2.1191

BibTeX
@article{Kong2023,
  author = {Kong, Lingping and Meng, Fanlu and Wu, Sijin and Zhou, Ping and Ge, Ruixin and Liu, Min and Zhang, Linlin and Zhou, Jun and Zhong, Diansheng and Xie, Songbo},
  title = {Selective degradation of the p53‐R175H oncogenic hotspot mutant by an RNA aptamer‐based PROTAC},
  journal = {Clinical and Translational Medicine},
  year = {2023},
  volume = {13},
  number = {2},
  doi = {10.1002/ctm2.1191}
}
Kostenlos starten →